Vancouver, bc,, March 17, 2025 / Prnewswire / – Biovaxys Technology Corp. (CSE: Biov) (Fra: 5LB) (OTCQB: Bvaxf) (“Biovaxys” Or “Business“) provides this bihebdomedary update on the state of the management of the commercial order granted on March 3, 2025 (THE “Mcto“), By its main regulator, the Commission of Securities of British Columbia (the” “BCSC) Under the national policy 12-203 – Assignment orders (“NP 12-203“). The company has announced February 13, 2025And March 3, 2025 (THE “Default ad“), that he was unable to deposit his annual financial statements audited for the finished financial year October 31, 2024The discussion and analysis of the related management, and its form 52-109FV1 CEO CEO and CFO of annual deposits (collectively “”Required deposit“). Under National Instrument 51-102 – Continuous disclosure obligationsThe required deposits were to be made at the latest February 28, 2025.
The company actively works with its listener, Dale Matheson Carr-Hilton Labonte LLP, to complete the required deposits, which will be deposited as soon as possible. As indicated above, subject to the current conditions remaining the same, the company remains confident in its ability to complete the deposits required by March 30, 2025.
Unless otherwise indicated by the present, there are no important changes to the information contained in the default ad. In addition, (i) the company is satisfactory and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and the issue of default reports Bihebdomadaires in the form of a press releases, as long as the company remains in default with its required depots; (ii) the company has no information for the moment concerning the default value specified after default in the filing of required deposits; (iii) the company confirms that, on the date of this press release, that the company is not subject to any insolvency procedure; and (iv) There is no other important information concerning the business of the company which has not been generally disclosed.
The company confirms that if the MCTO is in force, the general investment public will continue to be able to freely negotiate the listed ordinary shares of the company. However, the MCTO prohibits the chief executive officer of the company and financial director from negotiating titles of the company as long as the required deposits are not deposited. In addition, the company will be prohibited to issue directly or indirectly or acquire securities from initiates or employees of the company until the required deposits have been carried out and that all continuous disclosure requirements have been met by the company, and that the MCTO has been revoked.
About Biovaxys Technology Corp.
Biovaxys Technology Corp. (www.biovaxys.com), a biopharmaceutical company recorded in British Columbia, Canadais a biopharmaceutical company with clinical stage dedicated to improving the life of patients with new immunotherapies based on the DPX ™ technological platform ™ immune and it is haptenix “ neoantigenne ” of the tumor cell construction platform, for the treatment of cancers, infectious diseases, desensitization of antigens and other immunitological fields. The company’s clinical stadium pipeline includes Maveropepepimut-S found in clinical development of phase II for advanced cell B lymphoma (DLBCL) and platinum-resistant ovarian cancer, and BVX-0918 Spain For the treatment of ovarian cancer at an advanced refraction stage.
The company also capitalizes on its know-how of tumor immunology and the creation of a single library of T lymphocytes and other sets of post-vaccination data with its personalized immunotherapeutic vaccines to use predictive algorithms and other technologies to identify new target tumor antigens.
Biovaxys’ ordinary shares are listed on the Canadian Securities Stock Exchange under the “Biov” stock market symbol and are negotiated on the Frankfurt Stock Exchange (FRA: 5LB) and in the United States on over-the-counter markets (OTCQB Marketplace). For more information, visit www.biovaxys.com And connect with us to X and LinkedIn.
On behalf of the Board of Directors
Sign “James Passin“”
James PassinGeneral manager
Telephone: +1 740 358 0555
Declarations of precursation concerning information as the front approach
This press release includes certain “prospective information” and “prospective declarations” (collectively “prospective declarations“) Within the meaning of the legislation applicable on securities. All declarations, other than historical factual declarations, included here, without limitation, the declarations relating to the filing of the files required by March 30, 2025And the company’s ability to comply with the supply of alternative information guidelines described by NP 12-203, are prospective declarations. Prospective declarations are frequently, but not always, identified by words such as “wait”, “anticipate”, “believe”, “hear”, “esteem”, “potential”, “possible” and similar expressions, or declarations that events, conditions or results “,” can “,”, “could” or “should” occur or be reached. There is no guarantee that such declarations will prove to be exact, and real results and future events could differ materially from those expressed or involved in such prospective declarations.
These prospective declarations reflect beliefs, opinions and projections on the date on which the statements are made and are based on a certain number of assumptions and estimates, mainly the hypothesis that biovaxys will succeed in developing and testing vaccines, which, although considered reasonable by biovaxys, are inherent in significant, economic and social and social and social companies and Non-subbs. Many factors, known and unknown, could ensure that real results, performance or achievements are materially different from the results, performance or achievements that are or can be expressed or involved in such prospective declarations and the parties have made hypotheses and estimates based on or linked to many of these factors. These factors include, without limitation, the risk that the company will not be able to file the documents required by March 30, 2025. Biovaxys assumes no obligation to update the prospective declarations of beliefs, opinions, projections or other factors, if they change, unless applicable securities laws.
The Canadian Exchange of Securities has not examined, approved or disapproved of the content of this press release and does not accept responsibility for the adequacy or the accuracy of this press release.
Logo: https://mma.prnewswire.com/media/2415135/5221052/biovaxys_technology_corp_logo.jpg
Source Biovaxys Technology Corp.
